3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Breast
1
Conditions
Breast Neoplasms
9
Melanoma
4
Neoplasms
3
Multiple Myeloma
3
Skin Neoplasms
2
Polycystic Ovary Syndrome
2
Venous Thromboembolism
1
Triple Negative Breast Neoplasms
1
Thrombocythemia, Essential
1
Stem Cell Transplant Complications
1
Skin Toxicity
1
Resectable Pancreatic Ductal Adenocarcinoma
1
Renal Insufficiency
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Obesity
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Meningioma
1
Lymphoma, Mantle-Cell
1
Lung Neoplasms
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, B-Cell
1
Leukemia
1
Inflammation
1
Interventions
epigallocatechin gallate
2
XENP 1595
2
Etanercept
2
Ascorbic Acid
2
salicylsalicylic acid
1
microcrystalline cellulose
1
ginger extract
1
dapagliflozin
1
cytisine
1
Tablets
1
Sulindac
1
Spirometry
1
Specimen Handling
1
Sodium Salicylate
1
Radiotherapy, Conformal
1
Pregabalin
1
Omeprazole
1
Losartan
1
Ketorolac
1
Interleukin 1 Receptor Antagonist Protein
1
Infliximab
1
Hematologic Tests
1
Diet Therapy
1
Atorvastatin
1
Aspirin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Inflammation
×
Tablets
×
Clear all
NCT06150898
2025-06-13
KePreSt
Jules Bordet Institute
Phase 2
Recruiting
112 enrolled